Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.67 |
| ▸ | BCR | P11274 | 3/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.67 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | PRKACA | P17612 | 1/20 | 0.64 |
| ▸ | PRKACG | P22612 | 1/20 | 0.64 |
| ▸ | PRKACB | P22694 | 1/20 | 0.64 |
| ▸ | PRKCA | P17252 | 1/20 | 0.64 |
| ▸ | SYK | P43405 | 12/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.60 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386919 | 0.84 | ABL1 (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL4894535 | 0.84 | SYK (0.62) | ABL1BCRPRKCASYKCDK4 | |
| SCHEMBL7470857 | 0.84 | ABL1 (0.63) | ABL1BCREGFRPRKCASYK | |
| SCHEMBL7471678 | 0.83 | ABL1 (0.64) | ABL1BCRSRCPRKCASYK | |
| SCHEMBL5734023 | 0.83 | ABL1 (0.64) | ABL1BCRPRKCASYKCAMK2D | |
| SCHEMBL7469928 | 0.83 | ABL1 (0.64) | ABL1BCRPRKACAPRKCASYK | |
| Hydrochloric Acid SCHEMBL10769093 | 0.83 | SYK (0.60) | ABL1BCRPRKCASYKCDK4 | |
| SCHEMBL823915 | 0.83 | CAMK2D (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL2944432 | 0.82 | ABL1 (0.82) | ABL1BCRSRCEGFRPRKACA | |
| SCHEMBL4903688 | 0.82 | MAPK8 (0.63) | ABL1BCRPRKCASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | disclosed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | disclosed |
| EP-0233461-B2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-0233461-B1 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | ABL1 901/4885BCR 1338/4885SRC 796/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | ABL1 904/4885BCR 1230/4885SRC 724/4885 |
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | ABL1 2843/4885BCR 2315/4885SRC 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.